Investigation of mechanism of acquired chemoresistance for pancreatic cancer

Investigation of mechanism of acquired chemoresistance for pancreatic cancer - acquired chemoresistance in pancreatic cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042130

Enrollment

Registered

2020-10-15

Start date

2020-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The age at the time of registration is 20 years or older. 2) Invasive pancreatic duct cancer is diagnosed by pathological diagnosis. 3) Healed or unresectable lesion. 4) Chemotherapy is planned. 5) Provide a tumor (any one of 1 and 2) and a non-tumor tissue sample (1 and 3) that can be genetically analyzed. Tumor tissue 1 Residual sample after treatment 2 Tumor tissue sample newly collected for this study Non-tumor tissue 1 Residual sample after treatment 3 Peripheral blood sample newly collected for this study (10 mL) 6) Informed consent was obtained from the patient regarding participation in this study. 7) No concurrent double cancer (in case of metachronous double cancer, 5 years or more without recurrence after radical treatment). 8) Comprehensive informed consent has been obtained.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
Identification of acquired chemoresistant mutations in chemotherapy	—

Secondary

Measure	Time frame
Positive rate of liquid biopsy in pancreatic cancer Success rate of high-precision sequence analysis from minute samples	—

Countries

Japan

Contacts

Public ContactTadashi Uwagawa

The Jikei University School of Medicine Surgery

uwatadashi@msn.com03-3433-1111

Outcome results